Current Atherosclerosis Reports

, Volume 11, Issue 2, pp 81–83 | Cite as

Clinical trials report

  • John A. Farmer


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Smilde TJ, van Wissen S, Wollersheim H, et al.: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001, 357:577–581.PubMedCrossRefGoogle Scholar
  2. 2.
    Brown BG, Taylor AJ: Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med 2008, 358:1504–1547.PubMedCrossRefGoogle Scholar
  3. 3.
    During A, Dawson HD, Harrison EH: Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. J Nutr 2005, 135:2305–2312.PubMedGoogle Scholar
  4. 4.
    Greenland P, Lloyd-Jones D: Critical lessons from the ENHANCE trial. JAMA 2008, 299:953–955.PubMedCrossRefGoogle Scholar
  5. 5.
    Baigent C, Keech A, Kearney PM, et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267–1278.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2009

Authors and Affiliations

  • John A. Farmer

There are no affiliations available

Personalised recommendations